{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:02:30Z","timestamp":1790524950883,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.pcl.2018.09.011","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T21:41:11Z","timestamp":1542404471000},"page":"235-246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Hemolytic Uremic Syndrome"],"prefix":"10.1016","volume":"66","author":[{"given":"Ellen M.","family":"Cody","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley P.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"38\u201339","key":"10.1016\/j.pcl.2018.09.011_bib1","first-page":"905","article-title":"Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia","volume":"85","author":"Gasser","year":"1955","journal-title":"Schweiz Med Wochenschr"},{"issue":"3","key":"10.1016\/j.pcl.2018.09.011_bib2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5527\/wjn.v2.i3.56","article-title":"Update on hemolytic uremic syndrome: diagnostic and therapeutic recommendations","volume":"2","author":"Salvadori","year":"2013","journal-title":"World J Nephrol"},{"issue":"10095","key":"10.1016\/j.pcl.2018.09.011_bib3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.pcl.2018.09.011_bib4","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.pcl.2018.09.011_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ijlh.12671","article-title":"Diagnostic approach to microangiopathic hemolytic disorders","volume":"39","author":"Kottke-Marchant","year":"2017","journal-title":"Int J Lab Hematol"},{"issue":"6","key":"10.1016\/j.pcl.2018.09.011_bib6","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0022-3476(69)80346-X","article-title":"The hemolytic-uremic syndrome in nonrelated adopted siblings","volume":"75","author":"Chan","year":"1969","journal-title":"J\u00a0Pediatr"},{"issue":"10","key":"10.1016\/j.pcl.2018.09.011_bib7","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.4049\/jimmunol.0900151","article-title":"Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome","volume":"182","author":"Orth","year":"2009","journal-title":"J\u00a0Immunol"},{"issue":"12","key":"10.1016\/j.pcl.2018.09.011_bib8","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.2215\/CJN.02730409","article-title":"Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome","volume":"4","author":"Thurman","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.pcl.2018.09.011_bib9","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jama.288.8.996","article-title":"Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis","volume":"288","author":"Safdar","year":"2002","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.pcl.2018.09.011_bib10","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2215\/CJN.08921209","article-title":"Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome","volume":"5","author":"Nathanson","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.pcl.2018.09.011_bib11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/cid\/cis531","article-title":"An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children","volume":"55","author":"Loos","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.pcl.2018.09.011_bib12","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00467-012-2383-6","article-title":"Long-term outcomes of Shiga toxin hemolytic uremic syndrome","volume":"28","author":"Spinale","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1016\/j.pcl.2018.09.011_bib13","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1542\/peds.2004-2236","article-title":"Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion","volume":"115","author":"Ake","year":"2005","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.pcl.2018.09.011_bib14","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archpediatrics.2011.152","article-title":"Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome","volume":"165","author":"Hickey","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"10.1016\/j.pcl.2018.09.011_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamapediatrics.2016.2952","article-title":"Associations between hydration status, intravenous fluid administration, and outcomes of patients infected with Shiga Toxin-producing Escherichia coli: a systematic review and meta-analysis","volume":"171","author":"Grisaru","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"1","key":"10.1016\/j.pcl.2018.09.011_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1542\/peds.2015-2153","article-title":"Early volume expansion and outcomes of hemolytic uremic syndrome","volume":"137","author":"Ardissino","year":"2016","journal-title":"Pediatrics"},{"issue":"26","key":"10.1016\/j.pcl.2018.09.011_bib17","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJM200006293422601","article-title":"The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections","volume":"342","author":"Wong","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.pcl.2018.09.011_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/INF.0b013e31823096a8","article-title":"Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota","volume":"31","author":"Smith","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"10.1016\/j.pcl.2018.09.011_bib19","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jama.2012.264","article-title":"Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4","volume":"307","author":"Nitschke","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.pcl.2018.09.011_bib20","doi-asserted-by":"crossref","first-page":"e4565","DOI":"10.1136\/bmj.e4565","article-title":"Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study","volume":"345","author":"Menne","year":"2012","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.pcl.2018.09.011_bib21","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00467-010-1530-1","article-title":"Bleeding risk for surgical dialysis procedures in children with hemolytic uremic syndrome","volume":"25","author":"Weil","year":"2010","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1016\/j.pcl.2018.09.011_bib22","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00467-013-2414-y","article-title":"Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome","volume":"28","author":"Balestracci","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.pcl.2018.09.011_bib23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.tmrv.2016.06.004","article-title":"Clinical and laboratory consequences of platelet transfusion in Shiga toxin-mediated hemolytic uremic syndrome","volume":"31","author":"Beneke","year":"2017","journal-title":"Transfus Med Rev"},{"issue":"1","key":"10.1016\/j.pcl.2018.09.011_bib24","article-title":"Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura","author":"Michael","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.pcl.2018.09.011_bib25","first-page":"149","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: the seventh special issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J\u00a0Clin Apher"},{"issue":"26","key":"10.1016\/j.pcl.2018.09.011_bib26","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.pcl.2018.09.011_bib27","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E.\u00a0coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.pcl.2018.09.011_bib28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ndt\/gft470","article-title":"Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab","volume":"29","author":"Delmas","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.pcl.2018.09.011_bib29","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/cid\/cix218","article-title":"Intermediate follow-up of pediatric patients with hemolytic uremic syndrome during the 2011 outbreak caused by E.\u00a0coli O104:H4","volume":"64","author":"Loos","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.pcl.2018.09.011_bib30","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/jama.290.10.1337","article-title":"Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial","volume":"290","author":"Trachtman","year":"2003","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.pcl.2018.09.011_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/microbiolspec.EHEC-0013-2013","article-title":"New therapeutic developments against shiga toxin-producing Escherichia coli","volume":"2","author":"Melton-Celsa","year":"2014","journal-title":"Microbiol Spectr"},{"issue":"8","key":"10.1016\/j.pcl.2018.09.011_bib32","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1128\/IAI.73.8.4607-4613.2005","article-title":"Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications","volume":"73","author":"Sheoran","year":"2005","journal-title":"Infect Immun"},{"issue":"9797","key":"10.1016\/j.pcl.2018.09.011_bib33","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0140-6736(11)61253-1","article-title":"Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial","volume":"378","author":"Greinacher","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pcl.2018.09.011_bib34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00467-014-2918-0","article-title":"Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome","volume":"30","author":"Ardissino","year":"2015","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"10.1016\/j.pcl.2018.09.011_bib35","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.290.10.1360","article-title":"Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression","volume":"290","author":"Garg","year":"2003","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.pcl.2018.09.011_bib36","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s00467-007-0518-y","article-title":"Streptococcus pneumoniae-associated hemolytic uremic syndrome","volume":"23","author":"Copelovitch","year":"2008","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1016\/j.pcl.2018.09.011_bib37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MOP.0b013e32835d7f2c","article-title":"Update on Streptococcus pneumoniae associated hemolytic uremic syndrome","volume":"25","author":"Spinale","year":"2013","journal-title":"Curr Opin Pediatr"},{"issue":"11","key":"10.1016\/j.pcl.2018.09.011_bib38","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1111\/j.1537-2995.2008.01871.x","article-title":"A\u00a0severe case of atypical hemolytic uremic syndrome associated with pneumococcal infection and T activation treated successfully with plasma exchange","volume":"48","author":"Hopkins","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.pcl.2018.09.011_bib39","first-page":"9","article-title":"Management of Streptococcal pneumoniae-induced hemolytic uremic syndrome: a case report","volume":"2","author":"Weintraub","year":"2014","journal-title":"Clin Nephrol Case Stud"},{"issue":"3","key":"10.1016\/j.pcl.2018.09.011_bib40","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.mehy.2013.05.030","article-title":"Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae?","volume":"81","author":"Gilbert","year":"2013","journal-title":"Med Hypotheses"},{"issue":"9","key":"10.1016\/j.pcl.2018.09.011_bib41","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/ndt\/gft198","article-title":"The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome","volume":"28","author":"Szilagyi","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1016\/j.pcl.2018.09.011_bib42","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/INF.0b013e3182191c58","article-title":"Streptococcus pneumoniae-associated hemolytic uremic syndrome among children in North America","volume":"30","author":"Banerjee","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.pcl.2018.09.011_bib43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.pcl.2018.09.011_bib44","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.pcl.2018.02.003","article-title":"Atypical hemolytic uremic syndrome","volume":"65","author":"Dixon","year":"2018","journal-title":"Pediatr Clin North Am"},{"issue":"4","key":"10.1016\/j.pcl.2018.09.011_bib45","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.pcl.2018.09.011_bib46","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.pcl.2018.09.011_bib47","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-06-579953","article-title":"Loss of DGKepsilon induces endothelial cell activation and death independently of complement activation","volume":"125","author":"Bruneau","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pcl.2018.09.011_bib48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.pcl.2018.09.011_bib49","first-page":"127","article-title":"Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment","volume":"30","author":"Walle","year":"2017","journal-title":"J\u00a0Nephrol"},{"issue":"23","key":"10.1016\/j.pcl.2018.09.011_bib50","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.pcl.2018.09.011_bib51","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.pcl.2018.09.011_bib52","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.pcl.2018.09.011_bib53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.pcl.2018.09.011_bib54","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/ckj\/sfu144","article-title":"Remission of aHUS neurological damage with eculizumab","volume":"8","author":"Avila","year":"2015","journal-title":"Clin Kidney J"},{"issue":"21","key":"10.1016\/j.pcl.2018.09.011_bib55","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pcl.2018.09.011_bib56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1016\/j.pcl.2018.09.011_bib57","doi-asserted-by":"crossref","first-page":"e1764","DOI":"10.1542\/peds.2013-1594","article-title":"Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome","volume":"133","author":"Diamante Chiodini","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.pcl.2018.09.011_bib58","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.molimm.2017.05.013","article-title":"Complement in clinical medicine: Clinical trials, case reports and therapy monitoring","volume":"89","author":"Ricklin","year":"2017","journal-title":"Mol Immunol"},{"issue":"3","key":"10.1016\/j.pcl.2018.09.011_bib59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00467-013-2722-2","article-title":"Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab?","volume":"29","author":"Saland","year":"2014","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"10.1016\/j.pcl.2018.09.011_bib60","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.pcl.2018.09.011_bib61","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","article-title":"Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update","volume":"66","author":"Ardissino","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.pcl.2018.09.011_bib62","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.4081\/hr.2017.7053","article-title":"Atypical hemolytic uremic syndrome: a brief review","volume":"9","author":"Zhang","year":"2017","journal-title":"Hematol Rep"},{"issue":"3","key":"10.1016\/j.pcl.2018.09.011_bib63","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \"Kidney Disease: Improving Global Outcomes\" (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.pcl.2018.09.011_bib64","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jth.12615","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome","volume":"12","author":"Cugno","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"10.1016\/j.pcl.2018.09.011_bib65","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00467-017-3813-2","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update","volume":"33","author":"Ardissino","year":"2018","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.pcl.2018.09.011_bib66","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10545-010-9161-z","article-title":"Cobalamin C defect: natural history, pathophysiology, and treatment","volume":"34","author":"Martinelli","year":"2011","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"5","key":"10.1016\/j.pcl.2018.09.011_bib67","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10545-014-9687-6","article-title":"Clinical presentation and outcome in a series of 88 patients with the cblC defect","volume":"37","author":"Fischer","year":"2014","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"12","key":"10.1016\/j.pcl.2018.09.011_bib68","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00467-007-0604-1","article-title":"Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder","volume":"22","author":"Sharma","year":"2007","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395518301494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395518301494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:24:25Z","timestamp":1758475465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395518301494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0031395518301494"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2018.09.011","relation":{},"ISSN":["0031-3955"],"issn-type":[{"value":"0031-3955","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemolytic Uremic Syndrome","name":"articletitle","label":"Article Title"},{"value":"Pediatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcl.2018.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}